Crystal Structure of the Extracellular Domain of Mouse RANK Ligand at 2.2-Å Resolution*

Bone remodeling involves the resorption of bone by osteoclasts and the synthesis of bone matrix by osteoblasts. Receptor activator of NF-kB ligand (RANKL, also known as ODF and OPGL), a member of the tumor necrosis factor (TNF) family, triggers osteoclastogenesis by forming a complex with its receptor, RANK. We have determined the crystal structure of the extracellular domain of mouse RANKL at 2.2-Å resolution. The structure reveals that the RANKL extracellular domain is trimeric, which was also shown by analytical ultracentrifugation, and each subunit has a β-strand jellyroll topology like the other members of the TNF family. A comparison of RANKL with TNFβ and TNF-related apoptosis-inducing ligand (TRAIL), whose structures were determined to be in the complex form with their respective receptor, reveals conserved and specific features of RANKL in the TNF superfamily and suggests the presence of key residues of RANKL for receptor binding.

[1]  Brian R. Wong,et al.  TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.

[2]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[3]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[4]  S R Sprang,et al.  The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution. , 1992, The Journal of biological chemistry.

[5]  K. Sharp,et al.  Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons , 1991, Proteins.

[6]  D. Stuart,et al.  Structure of the TRAIL–DR5 complex reveals mechanisms conferring specificity in apoptotic initiation , 1999, Nature Structural Biology.

[7]  H. Yasuda,et al.  Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor. , 1998, European journal of biochemistry.

[8]  S. Mochizuki,et al.  Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. , 1997, Biochemical and biophysical research communications.

[9]  W. Hendrickson.  Determination of macromolecular structures from anomalous diffraction of synchrotron radiation. , 1991, Science.

[10]  J. Tavernier,et al.  Structure-activity studies of human tumour necrosis factors. , 1994, Protein engineering.

[11]  D. Banner,et al.  Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation , 1993, Cell.

[12]  M. Ueda,et al.  Cloning and characterization of the gene encoding mouse osteoclast differentiation factor. , 1999, Gene.

[13]  J. Thompson,et al.  2 A crystal structure of an extracellular fragment of human CD40 ligand. , 1995, Structure.

[14]  G. Sheldrick.  Phase annealing in SHELX-90: direct methods for larger structures , 1990 .

[15]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[16]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[17]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[18]  M. Ultsch,et al.  Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. , 1999, Molecular cell.

[19]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[20]  P. Kraulis.  A program to produce both detailed and schematic plots of protein structures , 1991 .

[21]  R F Standaert,et al.  Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin. , 1993, Journal of molecular biology.

[22]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[23]  A. Brunger.  Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. , 1992 .

[24]  M. Ultsch,et al.  A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. , 2000, Biochemistry.

[25]  M. S. Lee,et al.  Crystal Structure of TRAIL-DR5 Complex Identifies a Critical Role of the Unique Frame Insertion in Conferring Recognition Specificity* , 2000, The Journal of Biological Chemistry.

[26]  B. Matthews.  Solvent content of protein crystals. , 1968, Journal of molecular biology.

[27]  I. Wilson,et al.  Applications of the streak seeding technique in protein crystallization , 1991 .

[28]  B. Oh,et al.  2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. , 1999, Immunity.

[29]  D. I. Stuart,et al.  Structure of tumour necrosis factor , 1989, Nature.

[30]  T. Martin,et al.  Modulation of osteoclast differentiation. , 1992, Endocrine reviews.

[31]  A T Brünger,et al.  Protein hydration observed by X-ray diffraction. Solvation properties of penicillopepsin and neuraminidase crystal structures. , 1994, Journal of molecular biology.

[32]  H. Yasuda,et al.  RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. , 1998, Biochemical and biophysical research communications.

[33]  S. Sprang,et al.  The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. , 1990, The Journal of biological chemistry.

[34]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  E A Merritt,et al.  Raster3D: photorealistic molecular graphics. , 1997, Methods in enzymology.